These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 18466054)

  • 1. Alpha-synuclein and Parkinson's disease: a proteomic view.
    Fasano M; Lopiano L
    Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteomic approach in Parkinson's disease.
    Fasano M; Bergamasco B; Lopiano L
    Proteomics Clin Appl; 2007 Nov; 1(11):1428-35. PubMed ID: 21136640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
    Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
    Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
    Chu Y; Mickiewicz AL; Kordower JH
    Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathogenesis of Parkinson disease.
    Eriksen JL; Wszolek Z; Petrucelli L
    Arch Neurol; 2005 Mar; 62(3):353-7. PubMed ID: 15767499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
    Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
    Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
    Maguire-Zeiss KA; Short DW; Federoff HJ
    Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
    Sidhu A; Wersinger C; Vernier P
    FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis.
    Alberio T; Bossi AM; Milli A; Parma E; Gariboldi MB; Tosi G; Lopiano L; Fasano M
    FEBS J; 2010 Dec; 277(23):4909-19. PubMed ID: 20977677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease.
    Lashuel HA; Hirling H
    ACS Chem Biol; 2006 Aug; 1(7):420-4. PubMed ID: 17168518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic contributions to Parkinson's disease.
    Huang Y; Cheung L; Rowe D; Halliday G
    Brain Res Brain Res Rev; 2004 Aug; 46(1):44-70. PubMed ID: 15297154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies.
    Lim KL
    Expert Rev Proteomics; 2007 Dec; 4(6):769-81. PubMed ID: 18067415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lifetime proteomic profiling of an A30P alpha-synuclein Drosophila model of Parkinson's disease.
    Xun Z; Sowell RA; Kaufman TC; Clemmer DE
    J Proteome Res; 2007 Sep; 6(9):3729-38. PubMed ID: 17683129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.